Document is current

Any future updates will be listed below

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

Crossref DOI link: https://doi.org/10.1007/s00277-025-06713-3

Published Online: 2025-11-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark